AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37335760 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training 3 days/week (PT3, n = 17)
Number of subjects: 63
Study 37335760 — intervention group
Group type: COMPARATOR
Intervention: Wait Control (CON, n = 15)
Number of subjects: 63
Study 37335817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program, consisting of 8 weekly sessions lasting 2.5 hours each and a 6-hour silence retreat during week 6.
Number of subjects: 90
Study 37335817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 90
Study 37335885 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 70
Study 37335885 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 70
Study 37335885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 37335910 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning conversations (specific details on dosage and duration are not available)
Number of subjects: 0
Study 37335957 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT followed by TME surgery
Number of subjects: 1099
Study 37335957 — intervention group
Group type: COMPARATOR
Intervention: Up-front surgery
Number of subjects: 1099
Study 37335957 — intervention group
Group type: COMPARATOR
Intervention: Low-risk patients (up-front surgery)
Number of subjects: 1099
Study 37335957 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (nCRT followed by TME)
Number of subjects: 1099
Study 37335960 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus fludarabine (BuFlu) regimen
Number of subjects: 386
Study 37335960 — intervention group
Group type: COMPARATOR
Intervention: Busulfan plus cyclophosphamide (BuCy) regimen
Number of subjects: 386
Study 37335962 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA)
Number of subjects: 314
Study 37335962 — intervention group
Group type: EXPERIMENTAL
Intervention: intraoperative MRI (iMRI)
Number of subjects: 314
Study 37335962 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 314
Study 37335962 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 314
Study 37335963 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered concomitantly (Coad group)
Number of subjects: 545
Study 37335963 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered sequentially (Seq group)
Number of subjects: 545
Study 37335963 — intervention group
Group type: EXPERIMENTAL
Intervention: Coad group (mRNA-1273 and RZV1 concomitantly)
Number of subjects: 545
Study 37335963 — intervention group
Group type: COMPARATOR
Intervention: Seq group (mRNA-1273 and RZV1 sequentially)
Number of subjects: 545
Study 37335970 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D) group
Number of subjects: 24
Study 37335970 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 24
Study 37335976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation using the CENTAURI System with TactiCath SE, StablePoint, and ThermoCool ST ablation catheters
Number of subjects: 82
Study 37335976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation development Cohorts 1 and 2
Number of subjects: 82
Study 37335976 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized PFA Cohorts 3-5
Number of subjects: 82
Study 37335976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation
Number of subjects: 82
Study 37335976 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive remapping
Number of subjects: 82
Study 37335992 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin daily
Number of subjects: 19114
Study 37335992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 37335994 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 352
Study 37335994 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine-Pyridoxine
Number of subjects: 352
Study 37335994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Acupuncture and Doxylamine-Pyridoxine
Number of subjects: 352
Study 37335994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 37335995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination NRT (fast-acting form plus patch)
Number of subjects: 43327
Study 37335995 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 43327
Study 37335995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-acting form of NRT (gum or lozenge)
Number of subjects: 43327
Study 37335995 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT before quitting
Number of subjects: 43327
Study 37335995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose nicotine patches and gum
Number of subjects: 43327
Study 37335995 — intervention group
Group type: COMPARATOR
Intervention: NRT (various types)
Number of subjects: 43327
Study 37336007 — intervention group
Group type: EXPERIMENTAL
Intervention: Online opioid overdose and naloxone administration education (20-minute video)
Number of subjects: 194
Study 37336007 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone kit possession
Number of subjects: 194
Study 37336007 — intervention group
Group type: COMPARATOR
Intervention: Naloxone possession
Number of subjects: 194
Study 37336055 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel ≤12 mg/day
Number of subjects: 65
Study 37336058 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14 monoclonal antibody)
Number of subjects: 40
Study 37336058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37336228 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 26
Study 37336228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 37336535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive symptoms reported by participants with positive COVID-19 test results (self-reported as 'feeling disoriented or having trouble thinking')
Number of subjects: 3908
Study 37336535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive symptoms
Number of subjects: 3908
Study 37336535 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3908
Study 37336535 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (40-49 years)
Number of subjects: 3908
Study 37336535 — intervention group
Group type: EXPERIMENTAL
Intervention: History of autoimmune disease
Number of subjects: 3908
Study 37336535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung disease
Number of subjects: 3908
Study 37336535 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 3908
Study 37336535 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccination before infection
Number of subjects: 3908
Study 37336535 — intervention group
Group type: COMPARATOR
Intervention: Black race
Number of subjects: 3908
Study 37336533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten (starting dose 2.5 mg/day, adjusted during the study)
Number of subjects: 81
Study 37336533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 81
Study 37336533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 37336835 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative therapy consultation
Number of subjects: 182
Study 37336835 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative therapy prescription
Number of subjects: 182
Study 37336835 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 182
Study 37336835 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on breast cancer risk and prevention
Number of subjects: 182
Study 37336845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative flow disruptions (FDs)
Number of subjects: 61
Study 37336845 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipment- and patient-related FDs
Number of subjects: 61
Study 37336845 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of FDs
Number of subjects: 61
Study 37336877 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1010 (50 µg, 100 µg, or 200 µg)
Number of subjects: 0
Study 37336877 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1010 (25 µg, 50 µg, or 100 µg)
Number of subjects: 0
Study 37336877 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1010
Number of subjects: 0
Study 37337060 — intervention group
Group type: EXPERIMENTAL
Intervention: Genicular artery embolisation (GAE) using 100-micron Embozene™ microspheres
Number of subjects: 110
Study 37337060 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure using 0.9% saline
Number of subjects: 110
Study 37337059 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization with HepaSphere™ Microspheres 30-60 μm loaded with irinotecan (IRI-HEP-TACE)
Number of subjects: 100
Study 37337155 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-Ram (5-FU 2400 mg/m2)
Number of subjects: 429
Study 37337155 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and ramucirumab
Number of subjects: 429
Study 37337181 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pay-it-forward intervention of gonorrhea/chlamydia testing with minimal encouragement for testing
Number of subjects: 0
Study 37337181 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-engaged pay-it-forward arm
Number of subjects: 0
Study 37337181 — intervention group
Group type: COMPARATOR
Intervention: Control arm where men pay for their tests out-of-pocket
Number of subjects: 0
Study 37337181 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 37337208 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers FIRST program (adopters)
Number of subjects: 63
Study 37337208 — intervention group
Group type: COMPARATOR
Intervention: Non-adopters
Number of subjects: 63
Study 37337222 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate disclosure of genetic risk information
Number of subjects: 0
Study 37337222 — intervention group
Group type: COMPARATOR
Intervention: Deferred disclosure of genetic risk information
Number of subjects: 0
Study 37337234 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein content (2.0 g of protein/kg/day)
Number of subjects: 935
Study 37337234 — intervention group
Group type: COMPARATOR
Intervention: Standard protein content (1.3 g of protein/kg/day)
Number of subjects: 935
Study 37337243 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal hemoadsorption with VV ECMO
Number of subjects: 100
Study 37337261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment As Usual (TAU)
Number of subjects: 136
Study 37337261 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) alone
Number of subjects: 136
Study 37337261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 136
Study 37337269 — intervention group
Group type: EXPERIMENTAL
Intervention: Periradicular administration of platelet-rich fibrin (PRF) during surgery
Number of subjects: 60
Study 37337269 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 60
Study 37337295 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled xenon administered within 6 hours after the onset of symptoms of aSAH
Number of subjects: 0
Study 37337295 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37337366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide 600-μg
Number of subjects: 16
Study 37337366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 37337526 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 25mg
Number of subjects: 59
Study 37337526 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 1mg
Number of subjects: 59
Study 37337526 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 59
Study 37337747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 124
Study 37337747 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1-2 mg/day
Number of subjects: 124
Study 37337860 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia (PE) children
Number of subjects: 267
Study 37337860 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset PE children
Number of subjects: 267
Study 37337860 — intervention group
Group type: COMPARATOR
Intervention: Non-PE children
Number of subjects: 267
Study 37337896 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle HF Model (SHFM)
Number of subjects: 1643
Study 37337896 — intervention group
Group type: EXPERIMENTAL
Intervention: HF Meta-Score
Number of subjects: 1643
Study 37337896 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-Analysis Global Group in Chronic Heart Failure
Number of subjects: 1643
Study 37337896 — intervention group
Group type: COMPARATOR
Intervention: HF cardiologists
Number of subjects: 1643
Study 37337896 — intervention group
Group type: COMPARATOR
Intervention: Family doctors
Number of subjects: 1643
Study 37337948 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training intervention
Number of subjects: 158
Study 37337948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical phase angle (PhA) measurement
Number of subjects: 158
Study 37337948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 158
Study 37338010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 90
Study 37338010 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure
Number of subjects: 90
Study 37338010 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 90
Study 37338017 — intervention group
Group type: COMPARATOR
Intervention: 0.1-20.0 g/day alcohol use (moderate drinkers)
Number of subjects: 58769
Study 37338017 — intervention group
Group type: EXPERIMENTAL
Intervention: >20.0 g/day alcohol use (heavy drinkers)
Number of subjects: 58769
Study 37338017 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0 g/day alcohol use (non-drinkers)
Number of subjects: 58769
Study 37338130 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine for Reach, Education, Access, Treatment, and Ongoing Support (TREAT-ON) program
Number of subjects: 30
Study 37338130 — intervention group
Group type: COMPARATOR
Intervention: In-person DSMES delivered by a Diabetes Care and Education Specialist (DCES)
Number of subjects: 30
Study 37338150 — intervention group
Group type: EXPERIMENTAL
Intervention: Senaparib (100 mg QD)
Number of subjects: 57
Study 37338154 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS825 (10 mg/kg single i.v.) + standard of care (SoC)
Number of subjects: 138
Study 37338154 — intervention group
Group type: COMPARATOR
Intervention: Placebo + standard of care (SoC)
Number of subjects: 138
Study 37338154 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS825 + SoC
Number of subjects: 138
Study 37338158 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 274
Study 37338158 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (Prevnar 13)
Number of subjects: 274
Study 37338163 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cervical kinesthetic exercise (CKE) program
Number of subjects: 180
Study 37338163 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck exercises provided by the corresponding physical therapist
Number of subjects: 180
Study 37338163 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study 37338335 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic sleep staging system (ASSS) utilizing photoplethysmography and acceleration data from a smartwatch (MT2511)
Number of subjects: 75
Study 37338335 — intervention group
Group type: COMPARATOR
Intervention: Actiwatch Spectrum Plus
Number of subjects: 75
Study 37338335 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 75
Study 37338355 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics features in standard-dose CT (model I)
Number of subjects: 8878
Study 37338355 — intervention group
Group type: COMPARATOR
Intervention: Demographics in standard-dose CT
Number of subjects: 8878
Study 37338393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir, an oral antiviral drug targeting viral RNA polymerase, dosage and duration not specified.
Number of subjects: 0
Study 37338442 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label phase following the RCT
Number of subjects: 0
Study 37338442 — intervention group
Group type: COMPARATOR
Intervention: Hypnosis, mindfulness meditation, and pain education (RCT)
Number of subjects: 0
Study 37338442 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-open label phase assessments
Number of subjects: 0
Study 37338445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure treatment focusing on sexual assault trauma
Number of subjects: 0
Study 37338445 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure treatment not focusing on sexual assault trauma
Number of subjects: 0
Study 37338445 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SA history
Number of subjects: 0
Study 37338535 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-guided laparoscopic pancreaticoduodenectomy
Number of subjects: 82
Study 37338535 — intervention group
Group type: COMPARATOR
Intervention: Non-AR laparoscopic pancreaticoduodenectomy
Number of subjects: 82
Study 37338608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation with oral bisphosphonate, calcium and/or vitamin D
Number of subjects: 105
Study 37338608 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 105
Study 37338615 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 μg twice a day)
Number of subjects: 41
Study 37338615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 37338627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse AMIE (Addressing Metastatic Individuals Everyday) for 6 months
Number of subjects: 42
Study 37338627 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed for the first 3 months)
Number of subjects: 42
Study 37338729 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (not specified dosage or duration)
Number of subjects: 1617
Study 37338893 — intervention group
Group type: EXPERIMENTAL
Intervention: ApTOLL 0.2 mg/kg
Number of subjects: 139
Study 37338893 — intervention group
Group type: EXPERIMENTAL
Intervention: ApTOLL 0.05 mg/kg
Number of subjects: 139
Study 37338893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 37338898 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology Assisted Stepped Collaborative Care (TĀCcare) - 12 weekly sessions of cognitive behavioral therapy via telehealth and/or pharmacotherapy.
Number of subjects: 160
Study 37338898 — intervention group
Group type: COMPARATOR
Intervention: Attention control - 6 telehealth sessions of health education.
Number of subjects: 160
Study 37338906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted therapy (ADT) with nicotine patch (NP) and pharmacotherapy adaptations (varenicline and bupropion+NP)
Number of subjects: 392
Study 37338906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted therapy (ADT) with pharmacotherapy adaptations
Number of subjects: 392
Study 37338929 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring solutions and digital alerting tools
Number of subjects: 29
Study 37338929 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for enhancing integration of remote sensing solutions
Number of subjects: 29
Study 37338972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercises with internet support (NSEIT)
Number of subjects: 140
Study 37338972 — intervention group
Group type: COMPARATOR
Intervention: Neck-specific exercises supervised by a physiotherapist (NSE)
Number of subjects: 140
Study 37338977 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM mHealth app (n=42)
Number of subjects: 121
Study 37338977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary mHealth app (n=41)
Number of subjects: 121
Study 37338977 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 121
Study 37339000 — intervention group
Group type: EXPERIMENTAL
Intervention: PWID
Number of subjects: 578
Study 37339000 — intervention group
Group type: COMPARATOR
Intervention: Other patients
Number of subjects: 578
Study 37339000 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 578
Study 37339000 — intervention group
Group type: EXPERIMENTAL
Intervention: Latecomers to clinical visits
Number of subjects: 578
Study 37339167 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence, extension, and progression of subclinical atherosclerosis
Number of subjects: 391
Study 37339167 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Grim epigenetic age
Number of subjects: 391
Study 37339167 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis using transcriptomics and proteomics data
Number of subjects: 391
Study 37339173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR)-based care pathway
Number of subjects: 312
Study 37339173 — intervention group
Group type: COMPARATOR
Intervention: Invasive-based care pathway
Number of subjects: 312
Study 37339186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg daily plus rucaparib 400 mg twice daily
Number of subjects: 51
Study 37339254 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil 25 mg/m2 (days 1-5 of 14-day cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle)
Number of subjects: 28
Study 37339254 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus irinotecan
Number of subjects: 28